TNFRSF8 and anaplastic large cell lymphoma: A phase I dose-escalation study of brentuximab vedotin enrolled heavily pre-treated patients with relapsed/refractory CD30+ hematologic malignancies (Hodgkin lymphoma, n=42; systemic ALCL, n=2) (42).